Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready
Stealth BioTherapeutics Inc. manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area, currently featuring 6 pending office actions. These actions are distributed across 3 distinct art units, indicating a range of technical focuses within the company's research. The prosecution involves 5 distinct examiners, requiring a coordinated effort to manage multiple examiner interactions.
SHTERENGARTS, SAMANTHA L is the busiest examiner for this portfolio, currently managing 2 pending office actions. This examiner handles a portion of the 6 pending office actions, while the remaining actions are split among the other examiners. This distribution suggests that examiners are focused on specific applications within the portfolio, allowing for specialized review of each case.
With 5 distinct examiners and 3 distinct art units, the company must maintain a versatile prosecution strategy. The involvement of multiple examiners means that the company faces a variety of perspectives within the Biotechnology & Pharmaceuticals field. SHTERENGARTS, SAMANTHA L's role in overseeing 2 pending office actions is a point of focus for the company's current activity.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHTERENGARTS, SAMANTHA L | 2 | 79.5% | +8.0% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| TIEN, LUCY MINYU | 1 | 59.3% | +39.2% |
| OTTON, ALICIA L | 1 | 64.9% | +9.4% |
| KATAKAM, SUDHAKAR | 1 | 74.7% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18221140 | MITOCHONDRIA-TARGETING PEPTIDES | OTTON, ALICIA L | 55d |
| 18761854 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA | SHTERENGARTS, SAMANTHA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285570 | SILICA-BASED FORMULATIONS OF THERAPEUTIC OLIOGPEPTIDES AND PEPTIDOMIMETICS | TIEN, LUCY MINYU | 7d |
| 18011354 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | KATAKAM, SUDHAKAR | 26d |
| 18620789 | METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | NIEBAUER, RONALD T | 33d |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1612 | 1 |
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18761782 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA | SHTERENGARTS, SAMANTHA L | — | DP | Non-Final OA | — | Pending | Jul 02, 2024 |
| 18761854 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA | SHTERENGARTS, SAMANTHA L | — | §103§112Other | Non-Final OA | — | Pending | Jul 02, 2024 |
| 18620789 | METHODS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | NIEBAUER, RONALD T | 1658 | §103Other | Final Rejection | 33d | Pending | Mar 28, 2024 |
| 18285570 | SILICA-BASED FORMULATIONS OF THERAPEUTIC OLIOGPEPTIDES AND PEPTIDOMIMETICS | TIEN, LUCY MINYU | 1612 | §103DP | Final Rejection | 7d | Pending | Oct 04, 2023 |
| 18221140 | MITOCHONDRIA-TARGETING PEPTIDES | OTTON, ALICIA L | 1699 | §103§112 | Non-Final OA | 55d | Pending | Jul 12, 2023 |
| 18011354 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | KATAKAM, SUDHAKAR | 1658 | §103 | Non-Final OA | 26d | Pending | Dec 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial